GPP
Great Point Partners Portfolio holdings
AUM
$154M
This Quarter Return
+11.96%
1 Year Return
-2.36%
3 Year Return
+169.3%
5 Year Return
+292.82%
10 Year Return
+3,519.88%
AUM
$520M
AUM Growth
+$520M
(+14%)
Cap. Flow
+$47.1M
Cap. Flow
% of AUM
9.06%
Top 10 Holdings %
Top 10 Hldgs %
61.78%
Holding
46
New
9
Increased
7
Reduced
10
Closed
9
Top Buys
| 1 |
ARNA
Arena Pharmaceuticals Inc
ARNA
|
$41.2M |
| 2 |
Alnylam Pharmaceuticals
ALNY
|
$21.2M |
| 3 |
Cartesian Therapeutics
RNAC
|
$18.6M |
| 4 |
Pacira BioSciences
PCRX
|
$14.3M |
| 5 |
Insmed
INSM
|
$9.24M |
Top Sells
| 1 |
TherapeuticsMD
TXMD
|
$24.9M |
| 2 |
AVXS
AveXis, Inc. Common Stock
AVXS
|
$15.2M |
| 3 |
RXDX
Ignyta, Inc.
RXDX
|
$13.7M |
| 4 |
PRTK
Paratek Pharmaceuticals, Inc.
PRTK
|
$10.4M |
| 5 |
Aurinia Pharmaceuticals
AUPH
|
$7.34M |
Sector Composition
| 1 | Healthcare | 84.97% |
| 2 | Technology | 0.49% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
|
ARNA
1
DELISTED
Arena Pharmaceuticals Inc
ARNA
| $41.2M | 7.37% | +2,439,930 | New | +$41.2M |
|
|
ADMS
2
DELISTED
Adamas Pharmaceuticals, Inc.
ADMS
| $38.8M | 6.94% | 2,216,351 -385,000 | -15% | -$6.73M |
|
3
Vanda Pharmaceuticals
VNDA
$279M
| $36.4M | 6.52% | 2,232,238 | – | – |
|
|
ZGNX
4
DELISTED
Zogenix, Inc.
ZGNX
| $35.4M | 6.34% | 2,440,959 | – | – |
|
5
PTC Therapeutics
PTCT
$3.92B
| $34.8M | 6.24% | 1,900,000 +431,479 | +29% | +$7.91M |
|
|
SGYP
6
DELISTED
Synergy Pharmaceuticals, Inc Common Stock
SGYP
| $32.1M | 5.76% | 7,223,509 | – | – |
|
|
CNCE
7
DELISTED
Concert Pharmaceuticals, Inc.
CNCE
| $27.9M | 5% | 2,000,000 -200,000 | -9% | -$2.79M |
|
8
Neurocrine Biosciences
NBIX
$13.8B
| $27.6M | 4.94% | 600,000 +40,000 | +7% | +$1.84M |
|
9
Rigel Pharmaceuticals
RIGL
$697M
| $24.9M | 4.45% | 9,105,691 | – | – |
|
|
FOMX
10
DELISTED
Foamix Pharmaceuticals Ltd. Ordinary Shares
FOMX
| $22.2M | 3.97% | 4,781,708 +1,100,000 | +30% | +$5.1M |
|
|
11
Alnylam Pharmaceuticals
ALNY
$58.5B
| $22.1M | 3.96% | 276,800 +265,283 | +2,303% | +$21.2M |
|
|
SAGE
12
DELISTED
Sage Therapeutics
SAGE
| $19.4M | 3.48% | 243,800 -58,009 | -19% | -$4.62M |
|
|
13
Cartesian Therapeutics
RNAC
$261M
| $18.6M | 3.34% | +937,500 | New | +$18.6M |
|
|
RXDX
14
DELISTED
Ignyta, Inc.
RXDX
| $18.1M | 3.24% | 1,749,323 -1,321,977 | -43% | -$13.7M |
|
|
DBVT
15
DBV Technologies
DBVT
$264M
| $17.9M | 3.2% | 500,000 +14,085 | +3% | +$503K |
|
|
XLRN
16
DELISTED
Acceleron Pharma Inc.
XLRN
| $15M | 2.69% | 493,500 +193,500 | +65% | +$5.88M |
|
|
17
Pacira BioSciences
PCRX
$1.2B
| $14.3M | 2.56% | +300,000 | New | +$14.3M |
|
|
NDRM
18
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
| $9.3M | 1.67% | 311,000 -3,724 | -1% | -$111K |
|
|
19
Insmed
INSM
$28.8B
| $9.24M | 1.66% | +538,473 | New | +$9.24M |
|
|
AIMT
20
DELISTED
Aimmune Therapeutics, Inc.
AIMT
| $8.95M | 1.6% | 435,402 +312,947 | +256% | +$6.43M |
|
|
LUMO
21
DELISTED
Lumos Pharma, Inc. Common Stock
LUMO
| $8.03M | 1.44% | +1,092,849 | New | +$8.03M |
|
22
Apyx Medical
APYX
$75.3M
| $7.22M | 1.29% | 2,924,015 -130,985 | -4% | -$324K |
|
|
AMRN
23
Amarin Corp
AMRN
$311M
| $7.13M | 1.28% | +1,770,000 | New | +$7.13M |
|
|
GBT
24
DELISTED
Global Blood Therapeutics, Inc.
GBT
| $6.99M | 1.25% | 255,400 -44,600 | -15% | -$1.22M |
|
25
Dynavax Technologies
DVAX
$1.19B
| $4.2M | 0.75% | +435,500 | New | +$4.2M |
|